Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Değertekin B., Demir M., Akarca U. S., Kani H. T., Üçbilek E., Yıldırım E., ...Daha Fazla

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, cilt.31, ss.883-893, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/tjg.2020.20696
  • Dergi Adı: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.883-893
  • Anahtar Kelimeler: HCV, treatment, direct-acting antiviral, Turkey, SUSTAINED VIROLOGICAL RESPONSE, ACTING ANTIVIRAL THERAPY, HEPATOCELLULAR-CARCINOMA, HCV, INFECTION, RIBAVIRIN, CIRRHOSIS, TURKEY
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.